Ceragenix and MEGAPHARM Enter Into Distribution and Supply Agreement for EpiCeram[R].Megapharm to Register, Distribute and Market in Israel DENVER -- Ceragenix Pharmaceuticals  This article or section is written like an .Please help [ rewrite this article] from a neutral point of view. Mark blatant advertising for , using . , Inc.("Ceragenix") (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :CGXP), a medical device company focused on infectious disease Infectious disease A pathological condition spread among biological species. Infectious diseases, although varied in their effects, are always associated with viruses, bacteria, fungi, protozoa, multicellular parasites and aberrant proteins known as prions. and dermatology today announced that it has entered into an exclusive distribution and supply agreement (the "Agreement") with Megapharm Ltd., an Israeli company, ("Megapharm"), to commercialize EpiCeram[R], a topical cream for treating atopic dermatitis Atopic Dermatitis Definition Eczema is a general term used to describe a variety of conditions that cause an itchy, inflamed skin rash. Atopic dermatitis, a form of eczema, is a non-contagious disorder characterized by chronically inflamed skin and and other dry skin conditions in Israel and the Palestinian territories This article is about the Palestinian territories as a geopolitical phenomenon. For more on their geography, demographics and general history, see West Bank and Gaza Strip. The Palestinian territories (the "Territory"). The Agreement grants Megapharm exclusivity in the Territory for the distribution and marketing of EpiCeram[R] while Ceragenix will be responsible for the manufacturing and supply of the product. Megapharm is also responsible for obtaining regulatory clearance to market EpiCeram[R] in the Territory. Financial terms were not disclosed. Steven Porter Dr. Steven Porter (born 1943), BS MA PhD PD, is currently a candidate for the Third Congressional District of Pennsylvania. He is a teacher and composer, and in 1968 he became involved with politics when he helped Robert Kennedy in his presidential election campaign. Chairman and Chief Executive Officer of Ceragenix said, "We are pleased to expand our international distribution network for EpiCeram[R] by entering into this agreement with a well respected company such as Megapharm." Miron Drucker, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Megapharm, said "We are delighted to have forged an agreement with Ceragenix to market EpiCeram Cream in Israel. We have been active in dermatology for many years and this is an important step in the company's strategy to strengthen our presence and expand our portfolio in the dermatology field". About EpiCeram[R] EpiCeram[R] is a topical cream that utilizes Ceragenix's Barrier Repair Technology. In April 2006, the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. provided clearance to market EpiCeram[R] to improve dry skin conditions and to relieve and manage the burning and itching associated with various dermatoses including atopic dermatitis (eczema), irritant contact dermatitis irritant contact dermatitis Occupational dermatology A form of CD that usually affects the hands and arms, caused by acids, alkalis; the intensity of skin response reflects intrinsic nature of the chemical, its concentration, and duration of contact Clinical , radiation dermatitis radiation dermatitis n. See radiodermatitis. , and other dry skin conditions by maintaining a moist wound and skin environment. All of these conditions are associated with a deficient skin barrier function. About Ceragenix Ceragenix Pharmaceuticals, Inc. is a medical device company focused on infectious disease and dermatology. The Company has two base technology platforms; Ceragenins[TM] for treatment of infectious disease and Barrier Repair for the treatment of dermatological disorders including atopic dermatitis, neonatal skin disorders and others. Ceragenin[TM] compounds are active against a broad range of gram positive and negative bacteria. We have used our Ceragenin[TM] technology to formulate Cerashield[TM] antimicrobial coatings for medical devices. All Ceragenin[TM] and Cerashield[TM] products are currently in the developmental stage. Ceragenix's patented Barrier Repair technology, invented by Dr. Peter Elias Professor Peter Elias (Brunswick, November 26, 1923 - December 7, 2001) was a pioneer in the field of information theory. He was a member of the MIT faculty from 1953 to 1991 In 1955, Elias introduced convolutional codes as an alternative to block codes. , is the platform for the development of EpiCeram[R] which is currently being marketed by Promius Pharmaceuticals (a wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. of Dr. Reddy's Laboratories Dr. Reddy’s Laboratories Ltd. (Reddy's), founded in 1984 by Dr. K. Anji Reddy, has become India’s third biggest pharmaceutical company. Reddy had worked in the publicly-owned Indian Drugs and Pharmaceuticals Ltd. ) in the United States under an exclusive supply and distribution agreement. For additional information on Ceragenix, please visit www.ceragenix.com. About Megapharm Megapharm Ltd. is one of the leading private biotech, pharmaceutical and medical nutrition marketing companies in Israel with a strong biotech orientation, exclusively representing a number of major American and European pharmaceutical companies. Megapharm has demonstrated dynamic sales growth by developing a strong company presence and expertise in select therapeutic areas, and diversified segments of the healthcare business. The company also has a recognized and proven track record for obtaining reimbursement and inclusion of its products in all the health funds in Israel. For more information see www.megapharm.co.il FORWARD LOOKING STATEMENTS FOR CERAGENIX. This press release may contain forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, the following: the ability of Megapharm to successfully obtain marketing clearance for EpiCeram[R] in the Territory, the ability of the Company to raise sufficient capital to finance its operations and planned activities including completing development of its Ceragenin[TM] technology; the ability of the Company to meet its obligations under the supply and distribution agreement with Dr. Reddy's Laboratories including having sufficient working capital to fulfill purchase orders within the timeframes required by the agreement; the ability of the Company to service its outstanding convertible debt obligations; receiving the necessary marketing clearance approvals from the United States Food and Drug Administration United States Food and Drug Administration (FDA), n.pr a unit of the Public Health Service created to protect the health of the nation against impure and unsafe foods, drugs, and cosmetics. (the "FDA"); successful clinical trials of the Company's planned products including the ability to enroll the studies in a timely manner, patient compliance with the study protocol, and a sufficient number of patients completing the studies; the ability of the Company to commercialize its planned products; the ability of the Company to successfully manufacture its products in commercial quantities (through contract manufacturers); market acceptance of the Company's planned products, the Company's ability to successfully develop its licensed compounds, alone or in cooperation with others, into commercial products, the ability of the Company to successfully prosecute and protect its intellectual property, general economic conditions in the United States and elsewhere, and the Company's ability to hire, manage and retain qualified personnel. The aforementioned factors do represent an all inclusive list. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained in this press release. In particular important factors that could cause actual results to differ materially from our forward-looking statements including general economic factors, business strategies, the state of capital markets, regulatory conditions, and other factors not currently known to us, may be significant, now or in the future, and the factors set forth in this press release may affect us to a greater extent than indicated. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth in this press release and in other documents that we file from time to time with the Securities and Exchange Commission including its Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 2008, Quarterly Reports on Form 10-Q Form 10-Q See 10-Q. and Current Reports on Form 8-K Form 8-K The form required by the SEC when a publicly held company incurs any event that might affect its financial situation or the share value of its stock. Form 8-K See 8-K. to be filed in 2009. Except as required by law, we do not undertake any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion